Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$680M |
| 2 |
Microsoft
MSFT
|
+$506M |
| 3 |
UnitedHealth
UNH
|
+$393M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$381M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$348M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.24B |
| 2 |
Tesla
TSLA
|
+$450M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$444M |
| 4 |
TSMC
TSM
|
+$432M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 93.94% |
| 2 | Technology | 1.79% |
| 3 | Consumer Discretionary | 0.82% |
| 4 | Financials | 0.79% |
| 5 | Healthcare | 0.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CCRN
11426
CALL
DELISTED
Cross Country Healthcare
CCRN
| $163K | ﹤0.01% |
+12,500
| New | +$172K |
|
11427
CALL
Verastem
VSTM
$677M
| $163K | ﹤0.01% |
39,300
+4,200
| +12% | +$26.3K |
|
11428
CALL
Editas Medicine
EDIT
$505M
| $163K | ﹤0.01% |
74,100
-76,000
| -51% | -$124K |
|
|
YSG
11429
PUT
Yatsen Holding
YSG
$285M
| $163K | ﹤0.01% |
+16,900
| New | +$96.8K |
|
11430
CALL
Nuvectis Pharma
NVCT
$829M
| $163K | ﹤0.01% |
21,800
-51,100
| -70% | -$463K |
|
11431
CALL
Janus International
JBI
$685M
| $163K | ﹤0.01% |
20,000
+5,400
| +37% | +$41.2K |
|
11432
CALL
Kamada
KMDA
$473M
| $163K | ﹤0.01% |
21,000
+6,900
| +49% | +$46.8K |
|
11433
PUT
The Joint Corp
JYNT
$120M
| $163K | ﹤0.01% |
14,100
+3,800
| +37% | +$40.7K |
|
11434
Twin Disc
TWIN
$333M
| $163K | ﹤0.01% |
18,425
-10,515
| -36% | -$77.7K |
|
11435
PUT
Ocular Therapeutix
OCUL
$2.38B
| $162K | ﹤0.01% |
17,500
-13,100
| -43% | -$103K |
|
11436
PUT
LifeVantage
LFVN
$81.9M
| $162K | ﹤0.01% |
+12,400
| New | +$160K |
|
|
SLAI
11437
DELISTED
SOLAI Ltd ADS
SLAI
| $162K | ﹤0.01% |
11,299
+229
| +2% | +$2.92K |
|
|
DHF
11438
BNY Mellon High Yield Strategies Fund
DHF
$172M
| $162K | ﹤0.01% |
62,245
+2,423
| +4% | +$6K |
|
|
CD
11439
Chaince Digital Holdings
CD
$374M
| $162K | ﹤0.01% |
42,033
-157,917
| -79% | -$795K |
|
|
CUB
11440
Lionheart Holdings
CUB
$284M
| $162K | ﹤0.01% |
15,328
+3,233
| +27% | +$33.6K |
|
11441
CALL
Aquestive Therapeutics
AQST
$655M
| $162K | ﹤0.01% |
48,800
+4,600
| +10% | +$13.2K |
|
|
SLN
11442
Silence Therapeutics
SLN
$850M
| $161K | ﹤0.01% |
+27,797
| New | +$119K |
|
11443
Hyperfine
HYPR
$90.3M
| $161K | ﹤0.01% |
+223,794
| New | +$157K |
|
11444
PUT
Geron
GERN
$989M
| $160K | ﹤0.01% |
113,800
-123,200
| -52% | -$175K |
|
11445
Hennessy Advisors
HNNA
$79M
| $160K | ﹤0.01% |
12,734
-6,851
| -35% | -$73.2K |
|
11446
Lifezone Metals
LZM
$392M
| $160K | ﹤0.01% |
38,874
-9,734
| -20% | -$36.3K |
|
|
ICAD
11447
DELISTED
iCAD Inc
ICAD
| $160K | ﹤0.01% |
42,020
-120,061
| -74% | -$401K |
|
11448
PUT
Sasol
SSL
$7.33B
| $160K | ﹤0.01% |
36,200
-25,500
| -41% | -$104K |
|
11449
CALL
United Microelectronic
UMC
$47.8B
| $160K | ﹤0.01% |
20,900
-328,600
| -94% | -$2.44M |
|
|
ASRT
11450
CALL
DELISTED
Assertio
ASRT
| $160K | ﹤0.01% |
16,647
-9,026
| -35% | -$86.7K |
|
Similar funds
Jeff Yass's Q2 2025 Portfolio in Review
As of Q2 2025, Jeff Yass held 14,080 positions worth $720B, up 23% from $586B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass's Q2 2025 filing shows 1,720 new, 5,716 increased, 5,055 reduced and 1,538 closed positions. Its largest new stake was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.24B.
By sector, the portfolio is most concentrated in Miscellaneous at 94% of assets, down from 94% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q2 2025 buy was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
- Jeff Yass added most to Apple in Q2 2025, an estimated $680M increase.
- Jeff Yass's biggest Q2 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.24B.
- Jeff Yass fully exited Vanguard Intermediate-Term Bond ETF in Q2 2025, selling an estimated $61.8M.
- Jeff Yass's ten largest holdings make up 26% of its $720B portfolio in Q2 2025.
- Jeff Yass opened 1,720 new positions and closed 1,538 in Q2 2025.
- Jeff Yass's portfolio value rose 23% quarter-over-quarter to $720B.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.